Summary: In January 2024, according to publicly available market information, Israel's technology sector raised approximately $480 million in funding, with nearly half of the transactions focused on early-stage companies in A or seed rounds. Cybersecurity remains a hot investment area, with other major areas including agricultural technology, biotechnology, and artificial intelligence security. Israeli companies acquired include: Slauth.io, Easyway, Taro Pharmaceutical Industries, Helios, Authomize, and C2i Genomics.
Israeli companies which received investment in Jan 2024
| Company Name | Company Introduction |
| Joyned | Travel booking tech company |
| Aim Security | One-stop shop GenAI security platform |
| Oasis Security | Non-human identity management (NIM) solutions |
| Storage Drop | An energy firm that makes energy storage and cooling systems |
| Silk Security | A platform for sustainable cyber risk resolution |
| Chunk Foods | A company making plant-based whole cuts of alternative protein |
| Prompt Security | Enterprise-focused generative artificial intelligence security company |
| Sequence | A financial platform that aims to reshape personal finance management |
| Torq | Cyber startup |
| Silverfort | Unified Identity Protection company |
| Bluewhite | An agriculture service company that offers autonomous and smart transportation solutions for farmers |
| Better Juice | Better Juice innovates to reduce fruit juice sugar by up to 80% without sacrificing taste and nutrition |
| SeeTree | AI-based system that offers per-tree intelligence to growers to track the health and productivity of their trees |
| Vicarius | Autonomous end-to-end vulnerability remediation platform |
| Secret Double Octopus | Provides passwordless authentication solutions for the enterprise |
| Xyte | A hardware-as-a-service solution that allows companies to cloudify, service, support, and commercialize their connected devices |
| WaveBL | A tech company develops digital trade document solutions |
| Ask-AI | A generative AI answers and insights solution for enterprises |
| GeneNeer | An Ag tech company develops expedited, precisely-controlled gene editing and rapid gene discovery to support global food security and nutrition |
| Anecdotes | A leading technology provider for Compliance leaders |
| DigitalOwl | AI-Powered Medical Record Summarization Platform |
| XRHealth | A medical device company that develops an XR (VR\AR) therapeutic platform |
| QuantHealth | A company that creates artificial intelligence-based drug development data software |
| Aqua Security | Develops cloud native security solutions |
Israeli merger and acquisition deals in Jan 2024
1. Slauth.io, Identity and Access Management (IAM)
On January 31, 2024, according to BusinessWire, Ark Infotech LLC completed the acquisition of Slauth.io on December 31, 2023. The acquisition price has not been disclosed.
Located in Tel Aviv, Israel, Slauth.io is a pioneering cybersecurity and artificial intelligence company. Slauth has redefined the identity and access management (IAM) industry, offering AI-driven database optimization solutions.
Ark Infotech provides cybersecurity and cloud solutions to government agencies. This acquisition combines Slauth's advanced IAM technology with Ark Infotech's cybersecurity expertise to enhance the company's products in cloud platform cybersecurity and artificial intelligence innovation.
IAM: Stands for Identity and Access Management, a set of frameworks, policies, and technologies aimed at ensuring the right individuals in an organization can access the appropriate technology resources (such as systems, networks, or data) through the right means. The goal is to protect the organization's data and resources from unauthorized access threats while facilitating user access to necessary resources. IAM solutions typically involve key components such as identity authentication, authorization, user management, permission audits and compliance reporting, and single sign-on.
2. Easyway, Intelligent Hotel Guest Messaging Platform
On January 30, 2024, according to Phocuswire, the guest experience platform Duve announced the acquisition of Israeli hotel technology company Easyway. The acquisition price has not been disclosed.
Founded in 2016, Duve owns a leading guest experience platform in the hotel industry, known for its personalized guest management solutions. The platform focuses on creating customized digital AI-driven journeys for hotel guests, from online check-in to personalized upselling, covering various types of accommodations including hotels and vacation rentals.
Established in 2017, Easyway developed an AI-assisted platform for managing guest journeys, adopted by hundreds of hotels in Europe and Asia, including hotel chains. By seamlessly integrating with popular messaging apps and providing instant translation in over 100 languages, Easyway has completely transformed the way hotels communicate with guests. Easyway's first generative artificial intelligence significantly enhanced hotel operations, guest communication, and relationship building.
Duve stated that Easyway had successfully implemented generative artificial intelligence features, and the decision to acquire Easyway aligns with Duve's long-term vision of leading the hotel industry through technology. This acquisition marks an important milestone in the future development of personalized hotel technology.
3. Taro Pharmaceutical Industries, Research-based Pharmaceutical Company
On January 17, 2024, according to PR Newswire and Pharmaceutical Technology reports, the renowned Indian pharmaceutical company Sun Pharmaceutical and Israeli pharmaceutical enterprise Taro Pharmaceutical Industries (NASDAQ: TARO) announced that they have reached a final merger agreement. Sun Pharma will acquire all issued ordinary shares of Taro Pharmaceutical, excluding those already owned by Sun Pharma or its affiliates, for $347.73 million in cash ($43 per share without interest).
Sun Pharma is the fourth largest specialty generics company in the world, involved in specialty medicines, generics, and consumer health products, and is the largest pharmaceutical company in India, as well as a leading generics company in the United States and emerging global markets.
Taro Pharmaceutical Industries, established in Israel, holds a place in the development, manufacturing, and marketing of prescription and over-the-counter pharmaceutical products, especially in the field of dermatology. Taro is recognized for its innovation in the generics field, utilizing advanced manufacturing technologies to provide high-quality pharmaceuticals in the United States, Canada, and Israel.
Through this acquisition, Sun Pharma aims to leverage Taro's expertise and capabilities in generative artificial intelligence, combined with Sun Pharma's personalized customer management, to significantly enhance its position in the generic dermatological market.
4. Helios, Cybersecurity
On January 16, 2024, according to a Snyk official website announcement, Snyk has acquired Israeli cybersecurity company Helios. The acquisition amount has not been disclosed but is estimated to be in the tens of millions of dollars.
Founded in Israel in 2015, Snyk is a well-known developer security platform recognized for integrating security into the development process, making it easier for teams to address vulnerabilities in code, dependencies, containers, and infrastructure as code. Snyk's approach directly places security expertise in the hands of developers.
Helios, established in Tel Aviv, Israel, in 2021, focuses on capturing runtime data of applications. Helios' technology provides full-stack runtime data collection and insights, enhancing cloud-to-code risk visibility.
As software development accelerates, many companies seek to gain deeper insights into their applications' entire process from cloud to code to comprehensively understand their overall risk. Snyk's acquisition of Helios represents a significant leap in providing a more comprehensive view of applications throughout the software development lifecycle, enhancing DevSecOps collaboration.
DevSecOps Collaboration: Integrates security measures into the entire lifecycle of software development (Dev) and operations (Ops) for faster, safer software delivery. The goal of DevSecOps is to break down the barriers between traditional development, security, and operations, ensuring security becomes an inseparable part of the software development process through close collaboration across functional teams, emphasizing early identification and addressing of security issues to reduce the cost and risk of later repairs.
5. Authomize, Cross-Cloud Detection Cybersecurity
On January 9, 2024, according to Calcalist, the American company Delinea, a provider of seamless privileged access management (PAM) solutions, acquired Israeli cybersecurity company Authomize for tens of millions of dollars.
Delinea is a leading provider of privileged access management (PAM) solutions for modern hybrid enterprises. The Delinea platform seamlessly extends PAM by authorizing access to an organization's most critical hybrid cloud infrastructure and sensitive data for all identities, helping to reduce risk, ensure compliance, and simplify security. Delinea eliminates complexity and has defined access boundaries for tens of thousands of customers worldwide.
Authomize, founded in Tel Aviv, Israel, in 2019, has been recognized in the market for its innovative approach to detecting and mitigating identity-based threats across cloud platforms, using continuous discovery and visibility features to prevent account takeovers, insider threats, and lateral movement, and was named one of the most promising cybersecurity startups of 2021 by CRN.
This acquisition aligns with Delinea's strategy to enhance its PAM solutions with cloud infrastructure entitlement management (CIEM) and identity threat detection and response (ITDR) capabilities, expanding its scope of comprehensive privilege control in the cloud and strengthening defenses against identity-based attacks.
PAM: Stands for Privileged Access Management, a critical security strategy and technology aimed at controlling, regulating, and auditing privileged access to an organization's key systems and sensitive resources. Privileged access refers to access rights that can significantly impact the IT environment (such as operating systems, applications, databases, network devices, etc.), typically held by system administrators, IT professionals, or application accounts with elevated privileges. The goal of PAM is to reduce the likelihood of security risks and data breaches by ensuring only the appropriate personnel access sensitive resources at the right time and in the right manner.
6. C2i Genomics, Cancer Care
On January 8, 2024, according to Calcalist, the cancer diagnostics company Veracyte, Inc. (NASDAQ: VCYT) acquired Israeli cancer care company C2i Genomics for $95 million.
Veracyte provides genomics and molecular diagnostic services, recognized for its impact in changing cancer diagnosis and treatment globally. Its diagnostic platform is renowned for offering high-performance cancer tests driven by extensive genomic and clinical data, supported by deep bioinformatics and artificial intelligence (AI) capabilities.
C2i Genomics stands out for its AI-driven whole-genome MRD detection method, a significant advancement in early cancer detection and monitoring. Requiring only a minimal blood sample, C2i Genomics' solution offers a more effective, less invasive alternative to traditional methods. Its technology eliminates the need for custom biomarker panels by comparing a patient's tumor genome with their blood, enabling rapid, comprehensive insights into tumor dynamics.
The collaboration between Veracyte and C2i Genomics will usher in a new era of cancer diagnostics, emphasizing the importance of artificial intelligence and whole-genome sequencing in enhancing patient care. As Veracyte integrates C2i's technology, developing new diagnostic tests for various cancer types could significantly impact patient treatment outcomes, setting new standards for personalized cancer care.
MRD: Stands for Minimal Residual Disease, referring to the minute amounts of cancer cells that remain in the body after treatment, especially cancer treatment. MRD detection can be used to assess treatment effectiveness, predict the risk of recurrence, and guide subsequent treatment plans.
